Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)
Status:
Completed
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
This Phase II trial is studying how well giving epratuzumab together with an established
chemotherapy platform works in treating young patients with relapsed acute lymphoblastic
leukemia. Monoclonal antibodies, such as epratuzumab, can block cancer growth in different
ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and
help kill them or carry cancer-killing substances to them. Chemotherapy drugs work in
different ways to stop the growth of cancer cells, either by killing them or by stopping them
from dividing. Giving monoclonal antibody therapy in combination chemotherapy may kill cancer
cells more effectively.